Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

ASXL1 As a Potential Genetic Modifier in a Family with GATA2 Deficiency

Madeline VanDerGraaf, Kyle Dillahunt, Georgianne Younger, Diana K Bayer, Michael Halyko, Margarida Magalhaes-Silverman, Moon Ley Tung

Blood (2024) 144 (Supplement 1): 5711.

https://doi.org/10.1182/blood-2024-199791

Published: 2024

Journal Articles

Effect of NPM1 mutation Subtype and Co-Mutation Patterns on the Outcomes of Patients with Acute Myeloid Leukemia; A Referral Center Experience

Ratdanai Yodsuwan, Sarah L Mott, Kathryn Crawford, Grerk Sutamtewagul, Prajwal Dhakal, Margarida Magalhaes-Silverman, Kittika Poonsombudlert

Blood (2024) 144 (Supplement 1): 5949.

https://doi.org/10.1182/blood-2024-205891

Published: 2024

Journal Articles

Effect of Pre- and Peri-Transplant Measurable Residual Disease Clearance in Patients with Myelodysplastic Neoplasm; A Referral Center Experience

Ratdanai Yodsuwan, Sarah L Mott, Andrew Vegel, Aditya Ravindra, Prajwal Dhakal, Grerk Sutamtewagul, Margarida Magalhaes-Silverman, Kittika Poonsombudlert

Blood (2024) 144 (Supplement 1): 7422.

https://doi.org/10.1182/blood-2024-194001

Published: 2024

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

Clinical Outcomes of Patients Receiving 3 Versus 4 Doses of Methotrexate with Concomitant Anti-Thymocyte Globulin; A Single Center Experience

Kittika Poonsombudlert, Sarah L Mott, Brenda Miller, Hira Shaikh, Christopher Strouse, Jonathan Lochner, Umar Farooq, Margarida Magalhaes-Silverman

Blood (2023) 142 (Supplement 1): 2174.

https://doi.org/10.1182/blood-2023-181780

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma

Seth M Maliske, MD, Matthew J. Maurer, MS, Carrie A. Thompson, MD, Luis Porrata, MD, Ivana Micallef, MD, Rebecca L. King, MD, Sergei Syrbu, MD PhD, Brian K. Link, MD, Margarida Magalhaes Silverman, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, David James J Inwards, MD, Stephen M Ansell, MD PhD, James R. Cerhan, MD PhD, Patrick Johnston, MD PhD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 2896.

https://doi.org/10.1182/blood-2019-124579

Published: 2019

Journal Articles

Impact of Absolute Lymphocyte Count at Time of Antithymocyte Globulin on Outcomes of Allogeneic Unrelated Hematopoietic Cell Transplantation with Busulfan and Fludarabine Myeloablative Conditioning

Adithya Chennamadhavuni, MBBS, Kalyan Nadiminti, Lindsay Dozeman, Umar Farooq, MD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Sarah Mott, MS, Margarida Magalhaes Silverman, MD

Blood (2019) 134 (Supplement_1): 5671.

https://doi.org/10.1182/blood-2019-128186

Published: 2019

Journal Articles

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

Patrick Stiff, MD, Ivana Micallef, MD, Philip McCarthy, MD, Margarida Magalhaes-Silverman, MD, Neal Flomenberg, MD, Daniel Weisdorf, MD, Guido Tricot, MD, Mary Territo, MD, Rafat Abonour, MD, Karin Badel, Gary Calandra, MD/PhD

Blood (2004) 104 (11): 2847.

https://doi.org/10.1182/blood.V104.11.2847.2847

Published: 2004

NARROW

ASXL1 As a Potential Genetic Modifier in a Family with GATA2 Deficiency

Effect of NPM1 mutation Subtype and Co-Mutation Patterns on the Outcomes of Patients with Acute Myeloid Leukemia; A Referral Center Experience

Effect of Pre- and Peri-Transplant Measurable Residual Disease Clearance in Patients with Myelodysplastic Neoplasm; A Referral Center Experience

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Clinical Outcomes of Patients Receiving 3 Versus 4 Doses of Methotrexate with Concomitant Anti-Thymocyte Globulin; A Single Center Experience

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma

Impact of Absolute Lymphocyte Count at Time of Antithymocyte Globulin on Outcomes of Allogeneic Unrelated Hematopoietic Cell Transplantation with Busulfan and Fludarabine Myeloablative Conditioning

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only